Benjamin Yerxa
President & Director

Good morning, and thank you for joining us today to delve into our gene therapy pipeline with a focus on our earlier-stage programs. As a reminder, this event is being recorded.

Before we begin, I'd like to remind you that during today's call, we will be making certain forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Please refer to our annual and quarterly reports and our other SEC filings available on our website. Any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. A recording of this event and the accompanying slides will be available in the Events section of the Opus Genetics Investor Relations website later today.

So we have a really terrific lineup of speakers and are really grateful for all the key opinion leaders joining us today to share their expertise on the treatment of inherited retinal diseases, including target indications for Opus. For reference, you can access speaker bios on the right side of your screen or via the button in the top right corner.

Today's agenda is divided into 2 parts. In part 1, we will